Nivolumab
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 73/ 100
Competitive context
31 Active assets in the Gastroesophageal Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Memorial Sloan Kettering Cancer Center | Phase 3 | BB |
Cyclophosphamide Dispatch Biotherapeutics | Phase 3 | BB |
FLUOROURACILUM Memorial Sloan Kettering Cancer Center | Phase 3 | B |
Capecitabine Shanghai Zhongshan Hospital | Phase 3 | B |
Zanidatamab Tao Zhang | Phase 3 | B |
View all 34 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →